2022
Rationale and design of the SARCoidosis Outcomes in all respiratory Viral Infectious Diseases (SARCOVID) Study
Strykowski R, Patel DC, Neto MR, Hena KM, Gulati M, Maier LA, Patterson K. Rationale and design of the SARCoidosis Outcomes in all respiratory Viral Infectious Diseases (SARCOVID) Study. BMJ Open Respiratory Research 2022, 9: e001254. PMID: 35882424, PMCID: PMC9329732, DOI: 10.1136/bmjresp-2022-001254.Peer-Reviewed Original ResearchMeSH KeywordsCommunicable DiseasesCOVID-19HumansPandemicsProspective StudiesQuality of LifeSARS-CoV-2Treatment OutcomeConceptsLung functionRespiratory infectionsLocal institutional review board approvalFibrotic pulmonary sarcoidosisInstitutional review board approvalNon-infected patientsInterstitial lung diseaseRespiratory viral illnessReview board approvalViral infectious diseasesImpact of infectionPulmonary sarcoidosisViral illnessClinical courseInfectious eventsStudy entryStudy cohortPoor outcomeProspective studyLung diseaseLong-term impactLife measuresSarcoidosisHigh riskGeneral populationDisparities in Lung Transplant among Patients with Idiopathic Pulmonary Fibrosis: An Analysis of the IPF-PRO Registry
Swaminathan A, Hellkamp A, Neely M, Bender S, Paoletti L, White E, Palmer S, Whelan T, Dilling D, Baker A, Beegle S, Belperio J, Condos R, Cordova F, Culver D, Fitzgerald J, Flaherty K, Gibson K, Gulati M, Guntupalli K, Gupta N, Case A, Hotchkin D, Huie T, Kaner R, Kim H, Lancaster L, Lasky J, Lee D, Liesching T, Lipchik R, Lobo J, Luckhardt T, Mageto Y, Menon P, Morrison L, Namen A, Oldham J, Paul T, Zhang D, Porteous M, Raj R, Ramaswamy M, Russell T, Sachs P, Safdar Z, Shafazand S, Siddiqi A, Sigal B, Strek M, Suliman S, Tabak J, Walia R. Disparities in Lung Transplant among Patients with Idiopathic Pulmonary Fibrosis: An Analysis of the IPF-PRO Registry. Annals Of The American Thoracic Society 2022, 19: 981-990. PMID: 35073248, PMCID: PMC9169123, DOI: 10.1513/annalsats.202105-589oc.Peer-Reviewed Original ResearchMeSH KeywordsHumansIdiopathic Pulmonary FibrosisLung TransplantationProportional Hazards ModelsProspective StudiesRegistriesConceptsIdiopathic pulmonary fibrosisMedian ZIP code incomeZip code incomeLung transplant programsLung transplantProspective outcomes registryClinical characteristicsOutcomes RegistryPulmonary fibrosisTransplant programsSocial determinantsLung transplant centersDisease severity measuresIPF-PRO RegistryLikelihood of deathYears of ageLung transplantationPrespecified covariatesU.S. registriesDifferential associationsTransplant centersTransplant eligibilityClinical trialsTherapeutic modalitiesPatients
2020
The Pulmonary Fibrosis Foundation Patient Registry. Rationale, Design, and Methods.
Wang BR, Edwards R, Freiheit EA, Ma Y, Burg C, de Andrade J, Lancaster L, Lindell K, Nathan SD, Raghu G, Gibson K, Gulati M, Mason W, Noth I, Schmidt B, Spino C, Staszak S, Stauffer J, Wolters PJ, Cosgrove GP, Flaherty KR. The Pulmonary Fibrosis Foundation Patient Registry. Rationale, Design, and Methods. Annals Of The American Thoracic Society 2020, 17: 1620-1628. PMID: 32776789, DOI: 10.1513/annalsats.202001-035sd.Peer-Reviewed Original ResearchMeSH KeywordsAgedHumansIdiopathic Pulmonary FibrosisLung Diseases, InterstitialMaleProspective StudiesRegistriesRetrospective StudiesConceptsInterstitial lung diseasePatient RegistryClinician accessLarge multicenter registryMean diffusing capacityPositive smoking historyPercent of patientsIdiopathic pulmonary fibrosisTime of enrollmentIndividuals 18 yearsMulticenter registrySmoking historyPulmonary fibrosisSupplemental oxygenVital capacityLung diseaseMean agePatient populationAntifibrotic therapyApplicable biomarkersClinical informationDiffusing capacityPatientsClinical sitesRegistryAntifibrotic Drug Use in Patients with Idiopathic Pulmonary Fibrosis. Data from the IPF-PRO Registry
Salisbury M, Conoscenti C, Culver D, Yow E, Neely M, Bender S, Hartmann N, Palmer S, Leonard T, Baker A, Beegle S, Belperio J, Condos R, Cordova F, Culver D, Dilling D, Fitzgerald J, Flaherty K, Gibson K, Gulati M, Guntupalli K, Gupta N, Case A, Hotchkin D, Huie T, Kaner R, Kim H, Lancaster L, Lasky J, Lee D, Liesching T, Lipchik R, Lobo J, Luckhardt (formerly Joao de Andrade) T, Mageto Y, Malik N, Menon P, Morrison L, Namen A, Oldham J, Paul T, Podolanczuk A, Porteous M, Raj R, Ramaswamy M, Russell T, Sachs P, Safdar Z, Shafazand S, Siddiqi A, Sigal B, Strek M, Suliman S, Tabak J, Walia R, Whelan T. Antifibrotic Drug Use in Patients with Idiopathic Pulmonary Fibrosis. Data from the IPF-PRO Registry. Annals Of The American Thoracic Society 2020, 17: 1413-1423. PMID: 32574517, PMCID: PMC7640723, DOI: 10.1513/annalsats.201912-880oc.Peer-Reviewed Original ResearchMeSH KeywordsHumansIdiopathic Pulmonary FibrosisPharmaceutical PreparationsProspective StudiesQuality of LifeRegistriesConceptsIdiopathic pulmonary fibrosisIPF-PRO RegistrySelf-rated healthAntifibrotic medicationsEnrollment windowPulmonary fibrosisDiagnosis of IPFVital capacity percentageMajority of patientsWorse self-rated healthInterstitial lung diseaseProspective outcomes registryGreater disease severityEligible patientsU.S. registriesCarbon monoxide percentageLung biopsyPatient characteristicsMedication useOutcomes RegistrySleep apneaLung diseaseDefinite diagnosisClinical trialsFamily historyAssociations between Patient-reported Outcomes and Death or Lung transplant in IPF: Data from the IPF-PRO Registry
Case AH, Hellkamp AS, Neely ML, Bender S, Dilling DF, Gulati M, Hotchkin DL, Huie TJ, Lancaster L, Snyder LD, Conoscenti CS, Palmer S. Associations between Patient-reported Outcomes and Death or Lung transplant in IPF: Data from the IPF-PRO Registry. Annals Of The American Thoracic Society 2020, 0: 699-705. PMID: 32040340, PMCID: PMC7258421, DOI: 10.1513/annalsats.201906-437oc.Peer-Reviewed Original ResearchConceptsIdiopathic pulmonary fibrosisPatient-reported outcomesLung transplantClinical variablesSt. George's Respiratory Questionnaire total scoreSGRQ activity scoreUnderwent lung transplantClinical risk factorsPredictors of mortalityHealth-related qualityQuestionnaire total scoreIPF-PRO RegistryProspective outcomes registrySGRQ symptomsComposite outcomeExercise capacityActivity scoreOutcomes RegistryPulmonary fibrosisRisk factorsPhysical activityPatientsUnivariable modelsTransplantWorse scoresDisease Severity and Quality of Life in Patients With Idiopathic Pulmonary Fibrosis A Cross-Sectional Analysis of the IPF-PRO Registry
O’Brien E, Hellkamp A, Neely M, Swaminathan A, Bender S, Snyder L, Culver D, Conoscenti C, Todd J, Palmer S, Leonard T, investigators I, Asi W, Baker A, Beegle S, Belperio J, Condos R, Cordova F, Culver D, de Andrade J, Dilling D, Flaherty K, Glassberg M, Gulati M, Guntupalli K, Gupta N, Case A, Hotchkin D, Huie T, Kaner R, Kim H, Kreider M, Lancaster L, Lasky J, Lederer D, Lee D, Liesching T, Lipchik R, Lobo J, Mageto Y, Menon P, Morrison L, Namen A, Oldham J, Raj R, Ramaswamy M, Russell T, Sachs P, Safdar Z, Sigal B, Silhan L, Strek M, Suliman S, Tabak J, Walia R, Whelan T. Disease Severity and Quality of Life in Patients With Idiopathic Pulmonary Fibrosis A Cross-Sectional Analysis of the IPF-PRO Registry. CHEST Journal 2020, 157: 1188-1198. PMID: 31954102, DOI: 10.1016/j.chest.2019.11.042.Peer-Reviewed Original Research
2006
Clinical profile, diagnosis and management of patients presenting with symptomatic pulmonary embolism.
Agarwal R, Gulati M, Mittal B, Jindal S. Clinical profile, diagnosis and management of patients presenting with symptomatic pulmonary embolism. The Indian Journal Of Chest Diseases & Allied Sciences 2006, 48: 111-4. PMID: 16696525.Peer-Reviewed Original ResearchConceptsSymptomatic pulmonary embolismPulmonary embolismClinical profileLow molecular weight heparinOutcomes of patientsPulmonary artery hypertensionManagement of patientsMolecular weight heparinArtery hypertensionVentricular dyskinesiaAggressive managementClinical featuresPredominant complaintWeight heparinPerfusion scanMean ageEarly diagnosisProspective assessmentPatientsEmbolismSuccessful outcomeStudy periodDiagnostic methodsDiagnosisOutcomes